- Home
- BIOA vs MGNX Comparison
BIOA vs MGNX Comparison
Compare BIOA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- MGNX
- Stock Information
- Founded
- BIOA 2015
- MGNX 2000
- Country
- BIOA United States
- MGNX United States
- Employees
- BIOA N/A
- MGNX N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- BIOA Health Care
- MGNX Health Care
- Exchange
- BIOA Nasdaq
- MGNX Nasdaq
- Market Cap
- BIOA 139.1M
- MGNX 125.2M
- IPO Year
- BIOA 2024
- MGNX 2013
- Fundamental
- Price
- BIOA $3.82
- MGNX $1.26
- Analyst Decision
- BIOA Hold
- MGNX Hold
- Analyst Count
- BIOA 4
- MGNX 10
- Target Price
- BIOA $5.67
- MGNX $6.83
- AVG Volume (30 Days)
- BIOA 156.6K
- MGNX 647.7K
- Earning Date
- BIOA 05-15-2025
- MGNX 03-20-2025
- Dividend Yield
- BIOA N/A
- MGNX N/A
- EPS Growth
- BIOA N/A
- MGNX N/A
- EPS
- BIOA N/A
- MGNX N/A
- Revenue
- BIOA N/A
- MGNX $149,962,000.00
- Revenue This Year
- BIOA N/A
- MGNX N/A
- Revenue Next Year
- BIOA N/A
- MGNX $42.52
- P/E Ratio
- BIOA N/A
- MGNX N/A
- Revenue Growth
- BIOA N/A
- MGNX 155.26
- 52 Week Low
- BIOA $3.80
- MGNX $1.26
- 52 Week High
- BIOA $26.62
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- BIOA N/A
- MGNX 19.12
- Support Level
- BIOA N/A
- MGNX $1.89
- Resistance Level
- BIOA N/A
- MGNX $2.24
- Average True Range (ATR)
- BIOA 0.00
- MGNX 0.17
- MACD
- BIOA 0.00
- MGNX -0.07
- Stochastic Oscillator
- BIOA 0.00
- MGNX 0.00
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).